OTHER INFORMATION
−Removed: During the quarter ended June 30, 2025, no Director
−Removed: or Officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”
−Removed: as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the quarter ended September 30, 2025, no
+Added: Director or Officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading
+Added: arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
7 unchanged sentences
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized,
−Removed: on August 12, 2025.
+Added: on November 13, 2025.
SUNSHINE BIOPHARMA INC.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.